Geron Corp is primarily active in the biotechnology industry.

The main competitors of Geron Corp in the market include other pharmaceutical companies specializing in the field of oncology and stem cell research. Some prominent competitors of Geron Corp are Celgene Corporation, Biogen Inc., Johnson & Johnson, Novartis AG, and Amgen Inc. These companies also focus on developing innovative treatments and therapies for various types of cancer and other diseases.

Geron Corp, founded in 1990, is a biopharmaceutical company based in California, USA. The company focuses on the development of innovative therapeutic products for the treatment of cancer and other age-related diseases. Geron Corp has made significant advancements in the field of telomerase inhibition and embryonic stem cell research. Over the years, Geron Corp has collaborated with various renowned institutions and companies to advance its research and development efforts. With its commitment to pioneering medical breakthroughs, Geron Corp continues to strive towards improving patients' lives through the discovery and development of novel therapies.

Geron Corp has achieved several significant milestones. One of their key achievements includes the development of imetelstat, a telomerase inhibitor that shows promising potential in treating hematologic myeloid malignancies. Additionally, Geron Corp successfully completed the IMerge Phase 2 clinical trial, which demonstrated positive results in myelodysplastic syndromes (MDS) patients. The company also received Fast Track designation from the U.S. FDA for imetelstat in MDS, further highlighting its progress in advancing this innovative therapy. Geron Corp's ability to develop groundbreaking treatments and achieve important clinical trial milestones has positioned them as a leading player in the biopharmaceutical industry.

Geron Corp is primarily present in the United States.

Geron Corp is a biotechnology company that focuses on the development of innovative therapies to treat cancer and other diseases. The company prides itself on its commitment to scientific excellence, patient-centric approach, and dedicated team of skilled professionals. Geron Corp upholds a corporate philosophy rooted in transparency, integrity, and social responsibility. By prioritizing rigorous research and development, Geron Corp aims to deliver breakthrough treatments that can significantly improve patients' lives. With a strong emphasis on innovation and collaboration, the company continually strives to push the boundaries of medical science and make a positive impact in the healthcare industry.

Analysts currently set an average price target of 3.23 USD for the Geron stock (median: 3.57 USD), implying +105.7 % versus the latest price. The consensus is based on 13 analyst ratings.

Geron Analyst Price Targets 2026

13 analysts currently rate the Geron stock: 9 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Geron to generate revenue of 234.00 M USD and earnings per share of -0.02 USD.

Geron Analyst Price Targets 2026

Converted at the current exchange rate, the Geron share trades at 1.35 EUR (1.55 USD).

The Geron share (GERN) is listed on 7 stock exchanges, including: NASDAQ (GERN), Frankfurt (GON.F), München (GON.MU), Düsseldorf (GON.DU), London (0IV3.L), London (0IV3.L), SIX (Zürich) (GON.SW).

Geron Corp is an American biotechnology company that focuses on the development of therapeutics for diseases such as cancer and neurodegenerative disorders. The company was founded in 1990 and has been listed on NASDAQ since 1996. The company operates in two main divisions: oncology and regenerative medicine. Within each division, Geron Corp offers several products targeting different diseases and therapeutic approaches. Geron Corp's oncology division focuses on the development of therapeutics for cancer treatment. The company has developed a drug called Imetelstat, which has been tested in clinical trials for the treatment of various forms of cancer, including myelodysplastic syndrome (MDS), leukemia, and non-Hodgkin lymphoma. Imetelstat targets the inhibition of telomerase, an enzyme that is upregulated in many cancers and supports tumor cell growth. The company is also working on the development of immunotherapies and other novel treatment approaches for cancer. Geron Corp's regenerative medicine division focuses on the research and development of therapeutics for tissue and organ restoration and regeneration. The company has developed a technology called GRNOPC1, which targets neural precursor cells that can be used to repair damaged nerve tissue. The company is also working on the development of stem cell therapies for the treatment of heart and lung diseases, as well as other conditions that require tissue or organ regeneration. Geron Corp has established several partnerships with other companies in the biotechnology sector and pharmaceutical industry to support the development and commercialization of its products. The company also collaborates closely with academic research institutions and regulatory authorities to further develop and test its technologies and products. As a biotechnology company, Geron Corp heavily relies on the success of clinical trials and government approvals of its therapeutics. Investments in research and development of new products are significant, and the company's success depends on regularly bringing new therapeutics to market and successfully marketing its products. In summary, the business model of Geron Corp is based on the development and commercialization of novel therapeutics for the treatment of cancer and neurodegenerative diseases, as well as tissue and organ regeneration. The company operates in two main divisions, offers multiple products, and collaborates with various partners to support the development and commercialization of its products. As a biotechnology company, Geron Corp heavily depends on the success of its clinical trials and the approval of new products, and the company invests heavily in research and development to drive its growth.

The expected revenue of Geron is 234.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Geron is -13.38 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Geron is currently -77.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Geron stock.

The price-to-sales ratio (P/S) of Geron is currently 4.43. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Geron stock.

The Eulerpool Quality Score for Geron is 4/10.

The ISIN of Geron is US3741631036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Geron is 902213. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Geron is GERN. The ticker symbol is used to trade Geron shares on the stock exchange.

Geron paid dividends every year for the past 0 years.

Geron is assigned to the 'Health' sector.

The dividends of Geron are distributed in USD.